The use of PET imaging in Neurodegenerative Diseases

Please register to watch the webinar recording

In recent years, there was a paradigm shift in the diagnosis of neurodegenerative diseases, where the clinical testing is complemented by biomarker information. PET imaging with dedicated radiopharmaceuticals provides non-invasive biomarkers and co-morbidity information, which has brought a significant impact on clinical diagnosis and patient care. Imaging the human brain can provide unique information on the pathology and progression of neurodegenerative diseases like AD and PD. Imaging is also relevant for supporting preclinical and clinical trials of new therapeutic drugs.

Watch this webinar presented by 2 leading figures of Nuclear Medicine: Dr. Rosa-Neto and Dr. Dubroff. They gave a very instructive presentation about the use of PET imaging in Neurodegenerative Diseases.


  • Dr. Jacob Dubroff

    MD, PhD Dr. Dubroff is clinician scientist who uses Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography to better understand the molecular mechanisms of drug abuse, including nicotine dependence and opioid use disorder, as well as neurodegenerative disease, including Parkinson's and Alzheimer's diseases. He collaborates with investigators in the Departments of Psychiatry and Neurology. His studies are supported by the National Institute of Drug Abuse (NIDA), the National Heart, Lung, and Blood Institute (NHLBI), the Michael J. Fox Foundation, and industry.

  • Dr. Pedro Rosa-Neto

    MD, PhD Dr. Pedro Rosa-Neto MD (Federal University Rio Grande do Sul, Brazil), PhD (Aarhus University PET Centre, Denmark) is a professor of Neurology, Neurosurgery and Psychiatry at McGill University, affiliated to the Douglas Research Centre. He is a Fonds de Recherche Santé - Québec Senior Scholar. He is the Chair and National Coordinator of PET of the CIHR-Canadian Consortium on Neurodegeneration in Aging (CCNA) and vice chair of the CCNA team 2 'Inflammation and Trophic Factor deregulation in Alzheimer's disease. Dr. Rosa-Neto's directs the McGill University Research Centre for Studies in Aging and the laboratory for translational neuroimaging. Dr. Rosa-Neto research focuses on methodological aspects of amyloid, tau and neuroinflammation imaging in the context of clinical trials.